Loading...
Phase II study of liposomal muramyl tripeptide phosphatidylethanolamine (MTP/PE) in advanced soft tissue sarcomas of the adult. An EORTC Soft Tissue and Bone Sarcoma Group study.
Verweij, J Judson, I Steward, William P Coleman, R Woll, Penella J Van Pottelsberghe, C Van Glabbeke, Martine M Mouridsen, H
Verweij, J
Judson, I
Steward, William P
Coleman, R
Woll, Penella J
Van Pottelsberghe, C
Van Glabbeke, Martine M
Mouridsen, H
Citations
Altmetric:
Abstract
The EORTC Soft Tissue and Bone Sarcoma Group conducted a phase II study with intravenous muramyl tripeptide phosphatidylethanolamine (MTP/PE) at a dose of 4 mg once weekly in 20 patients with metastatic soft tissue sarcomas. Responses were not seen in 19 evaluable patients. Toxicity consisted mainly of a mild flu-like syndrome after 62% of drug administrations. It is concluded that MTP/PE at this dose and schedule has no activity in metastatic soft tissue sarcoma.
Description
Date
1994
Publisher
Collections
Keywords
Soft Tissue Cancer
Type
Article
Citation
Phase II study of liposomal muramyl tripeptide phosphatidylethanolamine (MTP/PE) in advanced soft tissue sarcomas of the adult. An EORTC Soft Tissue and Bone Sarcoma Group study. 1994, 30A (6):842-3 Eur. J. Cancer